FORM 3

## **UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

## INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

OMB APPROVAL						
OMB Number:	3235-0104					
Estimated average burden						
hours per response:	0.5					

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

GARNER CAM L	2. Date of Ever Requiring State (Month/Day/Ye 10/24/2006	ement	3. Issuer Name and Ticker or Trading Symbol  CADENCE PHARMACEUTICALS INC [ CADX ]							
(Last) (First) (Middle) C/O CADENCE PHARMACEUTICALS, INC.			Relationship of Reporting Person(s) to Issuer (Check all applicable)     X Director 10% Owner			5. If Amendment, Date of Original Filed (Month/Day/Year)				
12481 HIGH BLUFF DRIVE, SUITE 200			Officer (give title below)	Other (specify below)		Individual or Joint/Group Filing (Check Applicable Line)     X Form filed by One Reporting Person				
(Street) SAN DIEGO CA 92130						Form filed by More than One Reporting Person				
(City) (State) (Zip)										
Table I - Non-Derivative Securities Beneficially Owned										
1. Title of Security (Instr. 4)		2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownersh Form: Direct or Indirect ( (Instr. 5)	t (D) (Inst	ature of Indirect Beneficial Ownership tr. 5)					
Common Stock		435,000(1)	I	By Garner Investments, LLC <sup>(2)</sup>		nents, LLC <sup>(2)</sup>				
Common Stock		538,435(3)	I By		Garner Family Trust <sup>(4)</sup>					
Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)										
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of	5. Ownership Form: Direct (D)	6. Nature of Indirect Beneficial Ownership (Instr. 5)			
	Date Exercisable	Expiration Date	n Title	Amount or Number of Shares	Derivative Security	or Indirect (I) (Instr. 5)				
Series A-1 Preferred Stock <sup>(5)</sup>	(6)	(7)	Common Stock	26,595(8)	(9)	I	By Garner Investments, LLC <sup>(2)</sup>			
Series A-3 Preferred Stock <sup>(5)</sup>	(6)	(7)	Common Stock	25,000(8)	(9)	I	By Garner Investments, LLC <sup>(2)</sup>			

## **Explanation of Responses:**

- $1.\,17,\!500$  of these shares are subject to the Company's right to repurchase as of the date of this report, of which approximately  $2,\!188$  shares vest and are no longer subject to the Company's right to repurchase on the first day of each fiscal quarter until 07/01/2008.
- 2. Mr. Garner is the managing member of Garner Investments, LLC
- 3. 535,935 of these shares are subject to the Company's right to repurchase as of the date of this report. 85,125 shares vest and are no longer subject to the Company's right to repurchase on 12/30/2006, and approximately 7,094 shares vest and are no longer subject to the Company's right to repurchase on the 1st of each month thereafter until 12/01/2009. 48,858 shares vest and are no longer subject to the Company's right to repurchase on the 1st of each month thereafter until 2/01/2010.
- 4. Mr. Garner is the trustee of this trust.
- 5. These securities will automatically convert into Common Stock upon the closing of Cadence Pharmaceuticals, Inc.'s initial public offering.
- 6. Immediately convertible.
- 7. Not applicable.
- $8. \ Reflects \ a \ 1-for -4 \ reverse \ stock \ split, \ pursuant \ to \ which \ each \ share \ of \ Preferred \ Stock \ became \ convertible \ into \ 1/4 \ of \ a \ share \ of \ Common \ Stock.$
- 9. 4-for-1.

## Remarks:

/s/ Jennifer M. Repine, Attorney-in-fact 10/24/2006

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Know all by these presents, that the undersigned hereby authorizes Theodore R. Schroeder, William R. LaRue and Jennifer M. Repine of Cadence Pharmaceuticals, Inc. (the "Company"), and each of them individually to execute for and on behalf of the undersigned, in the undersigned's capacity as a director of the Company, Forms 3, 4 and 5, and any amendments thereto, and cause such form(s) to be filed with the United States Securities and Exchange Commission pursuant to Section 16(a) of the Securities Act of 1934, relating to the undersigned's beneficial ownership of securities in the Company. The undersigned hereby grants to each such attorney-in-fact full power and authority to do and perform any and every act and thing whatsoever requisite, necessary, or proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally present, with full power of substitution or revocation, hereby ratifying and confirming all that such attorney-in-fact, or such attorney-in-fact's substitute or substitutes, shall lawfully do or cause to be done by virtue of this power of attorney and the rights and powers herein granted. The undersigned acknowledges that the foregoing attorneys-in-fact, in serving in such capacity at the request of the undersigned, are not assuming, nor is the Company assuming, any of the undersigned's responsibilities to comply with Section 16 of the Securities Exchange Act of 1934.

This Power of Attorney shall remain in full force and effect until the undersigned is no longer required to file Forms 3, 4 and 5 with respect to the undersigned's holdings of, and transactions in, securities issued by the Company, unless earlier revoked by the undersigned in a signed writing delivered to the foregoing attorneys-in-fact.

IN WITNESS WHEREOF, the undersigned has cause this Power of Attorney to be executed as of this 18th day of October, 2006.

/s/ Cam L. Garner Cam L. Garner